Grifols reported EUR320.45M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Alaunos Therapeutics USD 447K 138K Mar/2026
Arca Biopharma USD 2.23M 1.08M Dec/2025
aTyr Pharma USD 700.63K 81.56M Mar/2026
Bio Path USD 259K 60K Mar/2026
Brainstorm Cell Therapeutics USD 1.21M 178K Mar/2026
Capricor Therapeutics USD 1.92M 446.47K Dec/2025
Cara Therapeutics USD 2.09M 96K Mar/2026
GlaxoSmithKline GBP 2.19B 75M Jun/2026
Grifols EUR 320.45M 12.65M Dec/2025
Immunic USD 3.45M 451K Dec/2025
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Nektar Therapeutics USD 11.87M 1.7M Mar/2026
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
TherapeuticsMD USD 1.23M 90K Jun/2024